Pharmacokinetic analysis of [
Child
Gallium Radioisotopes
Humans
Meningeal Neoplasms
/ diagnostic imaging
Meningioma
/ diagnostic imaging
Neoplasm Recurrence, Local
Octreotide
Organometallic Compounds
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Receptors, Somatostatin
/ genetics
Vascular Endothelial Growth Factor A
Meningioma
SSTR2
VEGFA
[68Ga]Ga-DOTA-TOC
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
08
11
2019
accepted:
04
03
2020
pubmed:
15
3
2020
medline:
15
5
2021
entrez:
15
3
2020
Statut:
ppublish
Résumé
DOTA-D-Phe Fifteen patients with MRI-presumed or recurrent meningiomas underwent a 60-min dynamic [ Histopathology revealed 12 World Health Organization (WHO) grade I and three WHO grade II meningiomas showing no link to SSTR2. The majority of [ [
Identifiants
pubmed: 32170347
doi: 10.1007/s00259-020-04759-1
pii: 10.1007/s00259-020-04759-1
doi:
Substances chimiques
Gallium Radioisotopes
0
Organometallic Compounds
0
Receptors, Somatostatin
0
Vascular Endothelial Growth Factor A
0
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2577-2588Subventions
Organisme : Kræftens Bekæmpelse
ID : R146-A9508-16-S2
Pays : International
Références
Ostrum QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(Suppl 5):iv1–100.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumurs of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
pubmed: 27157931
Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol. 2012;5(3):231–42.
pubmed: 22558478
pmcid: 3341686
Olar A, Wani KM, Sulman EP, et al. Mitotic index is an independent predictor of recurrence-free survival in meningiomas. Brain Pathol. 2015;25(3):266–75.
pubmed: 25040885
Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurg. 2009;64:56–60.
Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningiomas: a retrospective series. J Neuro-Oncol. 2012;109(1):63–70.
Attia A, Chan MD, Mott RT, et al. Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neurosurg. 2012;108:179–85.
Mazza E, Brandes A, Zanon S, et al. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trials by Gruppe Italiano Coorperativo di Neuro-On-cologia (GICNO). Cancer Chemother Pharmacol. 2016;77:115–20.
pubmed: 26659583
Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Oérez JM, et al. Meningiomas: a comparative study of
doi: 10.1371/journal.pone.0111624
pubmed: 25369268
pmcid: 4219730
Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222–7.
pubmed: 16488553
Afshar-Oronieh A, Giesel FL, Linhart HG, et al. Detection of cranial meningiomas: comparison of
Bashir A, Ziebell M, Fugleholm K, Law I. A potential role of 68Ga-DOTATOC PET in modifying eligibility to surgery in patients with recurrent meningioma. J Nucl Med Radiat Ther. 2015;6:256. https://doi.org/10.4172/2155-9619.1000256 .
doi: 10.4172/2155-9619.1000256
Hänscheid H, Sweeney RA, Flentje M, et al. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging. 2012;39(8):1284–8.
pubmed: 22526964
Bartolomei M, Bodei L, De Cicco C, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36(9):1407–16.
pubmed: 19319527
Marincek N, Radojewski P, Dumont RA, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56(2):171–6.
pubmed: 25593116
Seystahl K, Stoecklein V, Schüller U, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to
pubmed: 27106404
pmcid: 5063513
Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased
pubmed: 25635133
Dharmalingam P, Roopesh Kumar VR, Verma SK. Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma. Indian J Pathol Microbiol. 2013;56:349–54.
pubmed: 24441220
Barresi V, Alafaci C, Salpietro F, Tucari G. SSTR2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep. 2008;20:485–92.
pubmed: 18695896
Sommerauer M, Burkhardt JK, Frontzek K, et al.
pubmed: 26865086
pmcid: 4896546
Graillon T, Romano D, Defilles C, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg. 2017;127:660–9.
pubmed: 27982767
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16.
pubmed: 25763733
Ruuska T, Ramírez Escalante Y, Vaittinen S, et al. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
pubmed: 28686510
Pedersen SF, Sandholt BV, Keller SH, et al. 64Cu-DOTATATE PET/MRI for detection of activated macrophages in carotid atherosclerotic plaques: studies in patients undergoing endarterectomy. Arterioscler Thromb Vasc Biol. 2015;35(7):1696–703.
pubmed: 25977567
pmcid: 4479665
Hofmann M, Maecke H, Börner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751–7.
pubmed: 11734911
Koukouraki S, Strauss LG, Georgoulias V, et al. Comparison of the pharmacokinetics of
pubmed: 16763820
Poeppel TD, Binse I, Petersenn S, et al.
pubmed: 22072704
Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053–6.
pubmed: 11438627
Khalighi MM, Deller TW, Fan AP, et al. Image-derived input function estimation on a TOF-enabled PET/MR for cerebral blood flow mapping. J Cereb Blood Flow Metab. 2018;38(1):126–35.
pubmed: 28155582
Liptrot M, Adams KH, Martiny L, et al. Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. NeuroImage. 2004;21:483–93.
pubmed: 14980551
Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, et al. Characterization of
pubmed: 15872348
Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.
pubmed: 17519979
Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of
pubmed: 16437218
Ilan E, Sandström M, Velikyan I, et al. Parametric net influx rate images of (68)Ga-DOTATOC and (68)Ga-DOTATATE: quantitative accuracy and improved image contrast. J Nucl Med. 2017;58:744–9.
pubmed: 27789716
Velikyan I, Sundin A, Sörensen J, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55:204–10.
pubmed: 24379222
Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 2001;85(2):266–72.
pubmed: 11461088
pmcid: 2364037
Kurosaki M, Saegert W, Abe T, Lüdecke DK. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res. 2008;30(5):518–22.
pubmed: 18953743
Vilaume K, Blanc M, Gouysse G, et al. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology. 2010;91(3):268–78.
Preusser M, Hassler M, Birner P, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 2012;31(5):352–60.
pubmed: 22541785
Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology. 2015;17(1):116–21.
pubmed: 25100872
Ilan E, Velikyan I, Sandström, et al. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using
Pasquali D, Notaro A, Bonavolonta G, et al. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab. 2002;87:5125–9.
pubmed: 12414882
Menke JR, Raleigh DR, Gown AM, et al. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. [letter]. Acta Neuropathol. 2015;130(3):441–3.
pubmed: 26195322
Koper JW, Markstein R, Kohler C, et al. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab. 1992;74(3):543–7.
pubmed: 1346787
Pyronnet S, Bousquet C, Najib S, et al. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230–7.
pubmed: 18359151
Zhou T, Xiao X, Xu B, et al. Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signalling pathways. Acta Oncol. 2009;48(3):401–10.
pubmed: 18759148